NCT01849952

Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas

Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 94 (actual)
• Sponsor: Dartmouth-Hitchcock Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.

Conditions

• Astrocytoma
• Oligodendroglioma
• Oligoastrocytoma
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Anaplastic Oligoastrocytoma
• Glioblastoma
• Brain Tumors
• Brain Cancer

Timeline

• Start date: 2013-10-09
• Primary completion: 2024-04-12
• Completion: 2025-08-25
• First posted: 2013-05-09
• Last updated: 2025-09-15

Locations

4 sites across 1 country: United States